CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 28 enrolled
Drug / intervention
GSK2118436 +1 moredrug
Likely dose
GSK2118436 150 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01619774
NCT01619774Phase 2Completed
CompareCT.gov

An Open-Label Phase II Study of the Combination of GSK2118436 and GSK1120212 in Patients With Metastatic Melanoma Which is Refractory or Resistant to BRAF Inhibitor

M.D. Anderson Cancer Center·interventional·Posted Jun 14, 2012·Updated Dec 12, 2016

In Brief

A Phase 2 clinical trial evaluating GSK2118436 and GSK1120212 for Melanoma. Completed, enrolled 28 participants across 1 site.

Detailed Summary

The goal of this clinical research study is to learn if the combination of 2 drugs dabrafenib and trametinib can help to control melanoma that has or has not spread to the brain. The safety of this drug combination will also be studied. Dabrafenib is designed to block the mutated BRAF protein. This mutation is only found in moles of the skin and in melanoma cells. By blocking the protein, the drug may slow the growth of or kill cancer cells that have the protein. Trametinib is designed to block certain proteins that cause cancer cells to grow and multiply. This may cause the cancer cells to die.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMelanoma
CountriesUnited States
CollaboratorsCancer Prevention Research Institute of Texas, GlaxoSmithKline

Timeline

Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedJun 14, 2012
Enrollment StartSep 1, 2012
Primary CompletionAug 1, 2015
TodayJul 2, 2026
Enrollment to primary: 2.9 yearsPosted 14.0 years ago

Interventions

GSK2118436drug

Starting dose 150 mg by mouth twice a day.

GSK1120212drug

2 mg by mouth daily.